Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 12/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596237 | 0.88 | ALDH1A1 (0.46) | SUV39H2ALKABCB1LMNAMAPT | |
| SCHEMBL2589853 | 0.84 | SMN1; SMN2 (0.43) | SUV39H2ALKABCB1SMN1; SMN2HTT | |
| SCHEMBL2596018 | 0.79 | CHEK1 (0.61) | — | |
| SCHEMBL14965437 | 0.74 | HTR4 (0.41) | SUV39H2MAPT | |
| SCHEMBL14965412 | 0.74 | CHEK1 (0.41) | SUV39H2SMN1; SMN2LMNA | |
| SCHEMBL2596258 | 0.72 | LMNA (0.47) | SUV39H2ALKSMN1; SMN2HTTNPSR1 | |
| SCHEMBL1707770 | 0.71 | MAPT (0.57) | SUV39H2ALKABCB1SMN1; SMN2LMNA | |
| SCHEMBL15862951 | 0.71 | LMNA (0.54) | SUV39H2ALKABCB1SMN1; SMN2LMNA | |
| SCHEMBL2589855 | 0.71 | HTR4 (0.36) | SUV39H2 | |
| SCHEMBL2596022 | 0.71 | ALDH1A1 (0.35) | SMN1; SMN2LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716287-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| EP-2569290-A2 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141716-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | SUV39H2 3312/4885ALK 197/4885ABCB1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.